Key result
Targeting non-HDL-C emerges as a tailored alternative to sole LDL-C goals in combined dyslipidemia.
Why the study?
As obesity, diabetes, and metabolic syndrome increase, LDL-C may lose value as the sole lipid predictor of cardiovascular risk, prompting reconsideration of treatment targets in combined dyslipidemia.
No takes yet. Share an insight, caveat, or question.
May support non-HDL-C targeting in combined dyslipidemia; leaves open need for trials confirming outcome benefit over LDL-C alone.
Rizzo et al. (2013) conducted a review in Combined dyslipidemia. Non-HDL-C targeted treatment vs. LDL-C targeted treatment was evaluated. Increasing evidence suggests moving away from a sole LDL-C target-based approach to a more tailored treatment strategy, such as targeting non-HDL-C, for managing combined dyslipidemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: